Skip to main content

Advertisement

SpringerLink
Log in

Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to assess whether total-body [68 Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

Methods

Two hundred biochemical recurrent prostate cancer patients with similar clinicopathological characteristics were included, of whom 100 patients underwent early total-body [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT, and the other 100 patients received early conventional [68 Ga]Ga-PSMA-11 PET/CT and diuretic-delayed conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rates of total-body [68 Ga]Ga-PSMA-11 PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT were compared using a chi-square test and stratified analysis. The image quality of total-body [68 Ga]Ga-PSMA PET/CT and conventional [68 Ga]Ga-PSMA-11 PET/CT was compared based on subjective scoring and objective parameters. Subjective scoring was conducted from background noise and lesion prominence using a 5-point scale. Objective parameters were evaluated by SUVmax, SUVmean, the standard deviation (SD) of SUV, and the signal-to-noise ratio (SNR) of liver and gluteus maximus. The SUVmax of the recurrent lesions was also measured.

Results

The liver SD of the total-body [68 Ga]Ga-PSMA-11 PET/CT was significantly lower than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, the SNR was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT, and the subjective evaluation was significantly better than that of conventional [68 Ga]Ga-PSMA-11 PET/CT. The detection rate of total-body [68 Ga]Ga-PSMA PET/CT for biochemical recurrence of prostate cancer was significantly higher than that of conventional [68 Ga]Ga-PSMA-11 PET/CT (91.0% vs. 74.0%, P = 0.003). Total-body [68 Ga]Ga-PSMA-11 PET/CT had better detection efficiency for patients with a Gleason score ≤ 8 or PSA ≤ 2 ng/ml. The advantages of diuretic-delayed total-body [68 Ga]Ga-PSMA-11 PET/CT were more obvious.

Conclusion

Total-body [68 Ga]Ga-PSMA-11 PET/CT could significantly improve the detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data could be obtained from the corresponding author upon request.

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

    Article  PubMed  Google Scholar 

  2. Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int. 2010;106(1):37–43.

    Article  PubMed  Google Scholar 

  3. Huo H, Shen S, He D, Liu B, Yang F. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2023;26(1):16–24.

  4. Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61(2):285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59(1):3–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zhang X, Zhou J, Cherry SR, Badawi RD, Qi J. Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017;62(6):2465–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Tan H, Sui X, Yin H, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2021;48(6):1966–75.

    Article  CAS  PubMed  Google Scholar 

  10. Zhao YM, Li YH, Chen T, et al. Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(11):3378–85.

    Article  CAS  PubMed  Google Scholar 

  11. Zhang YQ, Hu PC, Wu RZ, et al. The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020;47(11):2507–15.

    Article  PubMed  Google Scholar 

  12. Fu F, Li X, Wu Y, et al. Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer. Eur J Nucl Med Mol Imaging. 2021;48(5):1678–9.

    Article  PubMed  Google Scholar 

  13. Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59(3):469–78.

    Article  PubMed  Google Scholar 

  14. van Sluis J, Boellaard R, Somasundaram A, et al. Image quality and semiquantitative measurements on the biograph vision PET/CT system: initial experiences and comparison with the biograph mCT. J Nucl Med. 2020;61(1):129–35.

    Article  PubMed  Google Scholar 

  15. Chen W, Liu L, Li Y, et al. Evaluation of pediatric malignancies using total-body PET/CT with half-dose [18F]-FDG. Eur J Nucl Med Mol Imaging. 2022;49(12):4145–55.

    Article  CAS  PubMed  Google Scholar 

  16. Van den Broeck T, van den Bergh RCN, Briers E, et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2020;6(2):231–4.

    Article  PubMed  Google Scholar 

  17. Fendler WP, Eiber M, Beheshti M et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–1486.

  18. Hohberg M, Kobe C, Täger P, et al. Combined early and late 68Ga-PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558–66.

    Article  CAS  PubMed  Google Scholar 

  19. Alberts I, Sachpekidis C, Gourni E, et al. Dynamic patterns of 68Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2020;47(1):160–7.

    Article  PubMed  Google Scholar 

  20. Alberts I, Niklas-Hünermund J, Sachpekidis C, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62(9):1252–7.

    Article  CAS  PubMed  Google Scholar 

  21. Kunikowska J, Pełka K, Tayara O, Królicki L. 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-impact of delayed imaging. J Clin Med. 2022;11(12):3311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rouvière O, Vitry T, Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur Radiol. 2010;20:1254–66.

    Article  PubMed  Google Scholar 

  23. Daub Witherspoon ME, Pantel AR, Pryma DA, Karp JS. Total-body PET: a new paradigm for molecular imaging. Br J Radiol. 2022;95(1140):20220357.

    Article  Google Scholar 

Download references

Funding

This study was supported by the National Key R&D Program of China (No. 2021YFA0910004); National Natural Science Foundation of China (No. 82171972); Clinical Research Project of Health Industry of Shanghai Municipal Health Commission (20214Y0438); and Nurture Projects for the Youth Medical Talents-Medical Imaging Practitioners Program (SHWRS(2021)_099).

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China

    Yining Wang, Zijun Chen, Haitao Zhao, Lianghua Li, Gang Huang, Ruohua Chen & Jianjun Liu

  2. Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China

    Yinjie Zhu & Wei Xue

Authors
  1. Yining Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zijun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yinjie Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haitao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lianghua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ruohua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jianjun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ruohua Chen or Jianjun Liu.

Ethics declarations

Ethical approval

The study involving human participants was in line with the principles of the ethics committee in Renji Hospital and the declaration of Helsinki in 1964. Animal-based research was not included in this study.

Consent to participate

Informed consent was obtained from all patients.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yining Wang and Zijun Chen are co-first authors and contributed equally to this manuscript.

Ruohua Chen and Jianjun Liu are co-corresponding authors and contributed equally to this manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Chen, Z., Zhu, Y. et al. Total-body [68 Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [68 Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 50, 4096–4106 (2023). https://doi.org/10.1007/s00259-023-06355-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-023-06355-5

Keywords

Search

Navigation